Furthermore, treatment could also involve monoclonal antibodies, including rituximab, which acts against CD20+ B cells, and mepolizumab, which inhibits the binding of interleukin-5 (IL-5) to its receptors expressed on eosinophils, improving cardiac function and reducing pericardial effusion [84]. This evidence concerns the gene IL5 and pericardial effusion.